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Summary
Primary hyperparathyroidism is a common disorder of mineral
metabolism characterized by incompletely regulated, exces-
sive secretion of parathyroid hormone from one or more of
the parathyroid glands. In adults with the disease, a single,
benign adenoma is seen approximately 80 percent of the time,
with multiple gland involvement making up for most of the re-
maining patients. Very rarely, a parathyroid cancer is respon-
sible but malignant parathyroid disease is rare, being seen in
less than 0.5 percent of patients with primary hyperparathy-
roidism. Primary hyperparathyroidism is the most common
cause of hypercalcemia and should always be considered in
any individual with hypercalcemia. In this article, we will re-
view important clinical and diagnostic features of primary hy-
perparathyroidism. We will review current recommendations
by which the clinician is guided as to the choice between
surgery and medical management, and focus then directly on
non-surgical options in the management of asymptomatic pri-
mary hyperparathyroidism. 
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Diagnosis
The diagnosis of primary hyperparathyroidism is generally very
straightforward, even though there are many causes of hyper-
calcemia. Since in primary hyperparathyroidism, parathyroid
hormone (PTH) is oversecreted, a PTH immunoassay that reli-
ably detects this increased PTH production is a cornerstone of
diagnosis. PTH levels by currently available immunoradiomet-
ric assay (IRMA) have the requisite sensitivity and specificity;
they reveal PTH levels that are either frankly elevated or in the
upper range of normal despite hypercalcemia. In malignancy,
the other most common cause of hypercalcemia, the PTH level
will be suppressed, even if the cause of the hypercalcemia in
malignancy is parathyroid hormone related protein (PTHrP).
The IRMA in general use in the United States for over 20
years, however, has recently been shown to detect not only the
full-length (1-84) amino acid molecule, but also amino terminal-
ly truncated forms of PTH (1). Recent studies report a mixture
of peptides similar in size to PTH (1-84) but with three to 14
amino acids deleted from the amino terminus (2); PTH (7-84) is
the most prominent of these species (2). These forms consti-
tute up to 50 percent of the circulating species of PTH in nor-
mal subjects (1, 2). In secondary hyperparathyroidism in renal
failure and in primary hyperparathyroidism these forms consti-
tute a higher percentage in the circulation than in normal sub-
jects (1, 2). An IRMA for PTH that measures only the biologi-
cally active, full-length molecule [PTH(1-84)] has become avail-
able (3, 4). The newer IRMA does not detect the large PTH
fragment. It remains to be seen whether this newer assay will
be shown to have more diagnostic utility in primary hyper-
parathyroidism (2, 3, 5). Silverberg et al. (5) compared this
newer assay with the older IRMA and a mid-molecule-specific
radioimmunoassay (RIA) in 56 subjects with primary hyper-
parathyroidism. The newer assay was shown to be elevated in
96 percent of subjects as compared to 73 percent and 63 per-
cent using the older IRMA and the RIA, respectively. However,
in chronic renal failure and secondary hyperparathyroidism
where the newer IRMA assays might be expected to more dis-
criminant, results appear similar (5a). The presumptive diagno-
sis of primary hyperparathyroidism in subjects whose calcium
and PTH levels are elevated has to take into account other sit-
uations in which the serum calcium and PTH levels can be ele-
vated. Drug-induced hypercalcemia due to lithium or thiazide
diuretics is readily apparent because of the history. In familial
hypocalciuric hypercalcemia (FHH), the PTH can also be ele-
vated, but it is distinguished from primary hyperparathyroidism
by family history and exceedingly low urinary calcium excre-
tion. If needed in the management of families suspected of
FHH, detection of a specific gene abnormality in the calcium
receptor can be sought (see other article in this series). 
Although most patients with primary hyperparathyroidism have
elevated serum calcium levels, a subgroup has been charac-
terized with normal serum calcium levels. Patients with normo-
calcemic primary hyperparathyroidism are distinct from patients
with primary hyperparathyroidism and abnormal PTH levels in
whom the serum calcium level is intermittently elevated. The
key consideration in this setting in which PTH levels are elevat-
ed when the serum calcium is normal, however, is not primary
hyperparathyroidism but secondary hyperparathyroidism in
which the parathyroid glands are appropriately responding to a
hypocalcemic stimulus. It is particularly important to rule out vit-
amin D insufficiency because it is so common in the popula-
tion. The initial descriptions of normocalcemic primary hyper-
parathyroidism included a requirement that 25-hydroxyvitamin
D (25(OH)D) levels had to be greater than 20 ng/ml. Maruani
et al. (6) and Silverberg and Bilezikian (7) have described pa-
tients in whom this situation exists. With a revision upwards in
the definition of sufficient vitamin D levels (8), it is important to
Asymptomatic primary hyperparathyroidism: present
management and future options
Mini-review
SYMPTOM TIC_Bilezikian  23/10/2006  12.34  Pagina 132
be sure that these patients are truly vitamin D sufficient. Vita-
min D repletion to levels of 25(OH)D that are greater than 30
ng/ml without an alteration in the elevated PTH levels is neces-
sary to sustain the diagnosis. Patients with normocalcemic pri-
mary hyperparathyroidism may represent the earliest manifes-
tations of primary hyperparathyroidism. 
An explanation for why this entity is being recognized more
commonly today may reside in the fact that many endocrinolo-
gists and other osteoporosis specialists evaluate the skeletal
status of women at risk for osteoporosis not only with determi-
nation of bone density but also with calciotropic hormone mea-
surements. When these patients are discovered, it is of interest
that certain clinical manifestations of primary hyperpara-thy-
roidism are already present (9, 10). It would appear that the hy-
perparathyroid process is being established in this earliest
phase of the disease when patients are not hypercalcemic.
The natural history of this variant of primary hyperparathy-
roidism is not known. Discussions in this article and others
generally do not address therapeutic and management recom-
mendations for these individuals because we do not know their
natural history. It is likely that some of these patients will devel-
op more overt primary hyperparathyroidism with hypercalcemia
but it is also possible that some of these patients will continue
to show elevated levels of PTH without hypercalcemia for
years, having achieved a new steady state that does not
progress. 
Evaluation
Skeletal manifestations
The demonstration of skeletal involvement in asymptomatic pri-
mary hyperparathyroidism depends upon dual energy X-ray
absorptiometry (DXA). Classical radiographic features are
rarely seen. DXA shows classic pathophysiological effects of
PTH in terms of a reduction in bone density of the distal third of
the radius, a site of cortical bone (11). The proclivity of PTH to
be catabolic for cortical bone is in constrast to its protective ef-
fect on cancellous bone (Fig. 1). Thus, at a site enriched in
cancellous bone, namely the lumbar spine, bone mineral den-
sity tends to be reasonably normal. At a site that contains a
more even admixture of cortical and cancellous elements,
namely the hip region, bone mineral density is intermediate be-
tween the cortical and cancellous sites. This pattern is seen
not only in unselected cohorts of subjects with primary hyper-
parathyroidism but also in postmenopausal women (12), in
whom one might expect to see selective reductions in lumbar
spine bone density because of the estrogen deficiency. Al-
though this classic densitometric profile is most commonly
seen, a distinctive pattern characterized by vertebral osteope-
nia can also be detected at the time of diagnosis (13). 
Histomorphometric analysis of the bone biopsy in primary hy-
perparathyroidism shows cortical thinning, maintenance of can-
cellous bone volume, and accelerated bone remodeling (14,
15). Other features emphasize the point that the cortical bone
compartment is at risk in primary hyperparathyroidism. The
biopsy studies have also shown that indices of trabecular con-
nectivity are actually greater than expected. Even the expected
age-dependent loss of cancellous bone is not seen in primary
hyperparathyroidism (14, 16-18). Based upon the densitomet-
ric data, it might be expected that the cortical skeleton would
be at greater risk than the cancellous skeleton for fracture. The
data are conflicting, however, with some studies showing an in-
crease and other studies no increase in incidence of vertebral
fractures (19-23). 
The retrospective review of a 28-year Mayo Clinic experience
concluded that overall fracture risk was increased at all sites
except the hip (24). Expectations of fracture incidence in pri-
mary hyperparathyroidism have to take into account other
skeletal effects of PTH besides a change in bone mineral den-
sity. If bone density were the only factor to consider, the distal
forearm would be the site at greatest risk. It is now clear that
bone density is only one of several important qualities of bone,
all of which are influential in the overall assessment of fracture
risk. Since PTH has important effects on some of these other
qualities of bone, such as bone size and microarchitecture, re-
ductions in bone mineral density may not directly relate to frac-
ture risk. For example, cortical thinning through PTH-mediated
endosteal resorption might be compensated in primary hyper-
parathyroidism by periosteal apposition, leading to bone that
may be increased in cross sectional diameter (25), as demon-
strated by Chen et al. (26) using pQCT technology. The in-
crease in bone size would give greater biomechanical protec-
tion, even though bone density is reduced. Additionally, it is im-
portant to consider the generally well-preserved cancellous mi-
croarchitecture in primary hyperpara-thyroidism, another factor
that might be protective. Thus, in primary hyperpara-thyroidism,
certain skeletal features tend to compete with each other: corti-
cal thinning favoring an increased fracture risk; increased bone
size and preserved microarchitecture favoring a reduction in
fracture risk. These considerations suggest the need for prospec-
tive studies of site-specific fracture incidence in primary hyper-
parathyroidism (27, 28).
Renal involvement
Although the incidence of nephrolithiasis is much less common
than its incidence in the classic, older presentation of primary
hyperparathyroidism, kidney stones remain the most common
manifestation of primary hyperparathyroidism, with estimates
placing the incidence of kidney stones now at 15 to 20 percent
(29). Other renal manifestations of primary hyperparathy-
roidism include hypercalciuria, which is seen in approximately
40 percent of patients, and nephrocalcinosis, the frequency of
which is unknown. 
Other organ involvement
Neurologic and cognitive signs or symptoms. Perhaps the most
common nonspecific complaints of patients with primary hyper-
parathyroidism are those of weakness and easy fatigability
(30). These complaints do not reflect the classic neuromuscu-
lar syndrome, in which type II muscle cell are dysfunctional
Figure 1 - The densitometric signature of primary hyperparathyroidism.
Bone mineral density is shown at all three skeletal sites in a cohort of pa-
tients with primary hyperparathyroidism. Note preferential involvement of
the distal radius, 1/3 site, with relative preservation of the lumbar spine
(Adapted from reference #12).
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(31). In asymptomatic primary hyperparathyroidism, this specif-
ic neuromuscular disorder is rarely seen (32). Nevertheless,
the nonspecific complaints of patients in this regard are note-
worthy. They often report some degree of constitutional, be-
havioral and/or psychiatric symptomatology and, in some stud-
ies, such symptoms have been documented by psychometric
testing (33). Reports exist in which there is apparent improve-
ment after successful parathyroid surgery (34-36), while others
have not been able to document changes postoperatively (36,
37). This issue remains unsettled. 
Cardiovascular system. Interest in the effect of primary hyper-
parathyroidism on cardiovascular function is rooted in patho-
physiologic observations of hypercalcemia in which hyperten-
sion, left ventricular hypertrophy and arrhythmias are common
(38-41). The impression shared among investigators at the re-
cent National Institutes of Health (NIH) Workshop on Asymp-
tomatic Hyperparathyroidism and reviewed in the summary
statement from that conference is that asymptomatic hyper-
parathyroidism is not associated with overt cardiovascular ab-
normalities (41, 53). It was noted that more severe forms of
hyperparathyroidism detected in some European centers (38-
40), especially when associated with hypertension, had left
ventricular hypertrophy and valvular calcifications with evi-
dence in some patients of regression after successful parathy-
roidectomy (38-41). In multiple endocrine neoplasia (MEN)
syndromes, the presence of pheochromocytoma or hyperal-
dosteronism could, of course, lead to cardiovascular manifes-
tations. In asymptomatic primary hyperparathyroidism, hyper-
tension, when present, does not change after successful
parathyroid surgery. Whether any cardiovascular abnormali-
ties are demonstrable in mild asymptomatic primary hyper-
parathyroidism will require highly sensitive measurements of
cardiovascular function (42-44). 
Vitamin D in primary hyperparathyroidism
In countries where biochemical screening tests are not routine-
ly employed, more classic presentations of primary hyper-
parathyroidism overtly involving the skeleton and the kidneys
are described as common occurrences (45-47). Lack of routine
screening tests helps, in part, to explain these findings but it is
not an adequate explanation by itself. Vitamin D deficiency is
also common, in countries where primary hyperparathyroidism
is a symptomatic disorder, an observation that fits with the pro-
posal made years ago by Lumb and Stanbury that primary hy-
perparathyroidism is worse in the presence of vitamin D defi-
ciency (48). Even in mild, asymptomatic primary hyperparathy-
roidism, it has been shown that low 25(OH)D levels are associ-
ated with increased indices of disease activity (49). In these
patients with primary hyperparathyroidism, it seems reasonable
to consider restoring vitamin D to sufficient levels. The ratio-
nale is that to a certain extent, vitamin D deficiency may be fu-
eling the pathophysiological processes associated with poorly
controlled PTH secretion. By restoring vitamin D levels to nor-
mal, that component of the PTH secretory drive would be ame-
liorated. Despite the attractiveness of this approach, providing
vitamin D to these individuals could raise their serum calcium
further. To address this question, Grey et al. (50) recently re-
ported on 21 patients with mild primary hyperparathyroidism
whose 25(OH)D levels were < 20 ng/ml. Repletion was accom-
plished by the administration of vitamin D3 (cholecalciferol),
50,000 IU weekly (1 tablet), for the first month and then 50,000
IU monthly for the next 12 months. The baseline serum calcium
was 10.8 ± 0.5 mg/dl. PTH was 138 ± 70 pg/ml (nl: 10-65) and
the 25(OH)D level was 11 ± 5 ng/ml (nl reference range, 11-
55). Mean 25(OH)D levels after 6 and 12 months of vitamin D
repletion were 30 ± 7 ng/ml and 31 ± 6 ng/ml, respectively. The
serum PTH level declined by an average of 25 percent during
vitamin D repletion, but the serum calcium did not change.
There was a significant relationship between the increase in
the 25(OH)D and the fall in serum PTH levels. Although urinary
calcium excretion did not change significantly in most treated
individuals, three of the 21 study subjects developed marked
hypercalciuria (> 400 mg/day). There was a tendency for bone
turnover markers to fall, but only the 12-month total alkaline
phosphatase activity showed a significant decline. Although
this report does give a rationale as to the safety for providing
vitamin D to subjects with primary hyperparathyroidism, it re-
mains clear that caution is needed and patients should be fol-
lowed closely to detect worsening hypercalcemia or hypercalci-
uria. 
Treatment options in asymptomatic primary 
hyperparathyroidism
This discussion is focused entirely upon the patient with
asymptomatic primary hyperparathyroidism. Patients with
symptoms or signs such as fractures, renal stones and the
classic neuromuscular manifestations of primary hyper-
parathyroidism should have surgery. Since many patients,
however, are not symptomatic, it is important to consider how
best to treat these individuals. For example, it is quite reason-
able to question the advisability of surgery in all patients with
asymptomatic disease. Since many patients with primary hy-
perparathyroidism are known to have the disease only be-
cause an incidental serum calcium determination was ob-
tained, it is possible the disease would have remained unrec-
ognized without the serum calcium measurement. In fact, in
their long-term natural history study of asymptomatic primary
hyperparathyroidism, Silverberg and Bilezikian have shown
that in some patients with asymptomatic primary hyper-
parathyroidism, the course is benign (51). Given the observa-
tion that some of these individuals do have an uneventful nat-
ural history, non-surgical approaches would appear to be a
reasonable alternative. On the other hand, some patients, al-
though asymptomatic, may have levels of serum and/or uri-
nary calcium that are sufficiently above normal to give concern
as to the wisdom of following them long term. In these asymp-
tomatic individuals, bone mineral density measurements that
are low could be a clue that they are at increased fracture risk,
especially given the uncertainty about the effects of PTH ex-
cess on skeletal fragility.
These issues related to the management of asymptomatic pri-
mary hyperparathyroidism have been addressed at two NIH
conferences, one held in 1990 (52) and more recently in 2002
(53, 54). The 2002 conference was held because the guide-
lines for surgery emanating from the meeting held 12 years be-
fore were felt to be in need of revision in light of new knowl-
edge about key issues that had since become evident. Al-
though the conference was not designed to discuss sympto-
matic disease, it was again emphasized that all symptomatic
patients be advised to undergo parathyroidectomy.
The proposed quidelines (53) were revised modestly from
those offered at the earlier conference (52) primarily to reflect
greater conservatism about recommending medical manage-
ment and monitoring as opposed to surgery. Principally, these
changes involved lowering the acceptable upper levels of
serum calcium elevations from 1.6 mg/dl above normal to 1.0
mg/dl above normal and tightening skeletal surveillance by rec-
ommending monitoring at three sites, using the T-score rather
than Z-score cut-off to emphasize the importance of departure
from optimum bone mass as an indication for surgery.
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For asymptomatic patients, surgery is advised if any one of the
following criteria is met: (1) serum calcium concentration
greater than 1 mg/dl above the upper limits of normal; (2)
marked hypercalciuria (> 400 mg/day) or reduction in creati-
nine clearance by more than 30 percent below age- and sex-
matched reference values; (3) markedly reduced bone density
(T-score <-.2.5 at any site); and (4) age less than 50 years.
Table I summarizes these guidelines. Although these guide-
lines have been very useful for clinicians who are faced with
the dilemma: to operate or not, it should be noted that surgery
for asymptomatic patients who do not meet any of these guide-
lines is not necessarily ill-advised. Surgery for asymptomatic
primary hyperparathyroidism is always a valid option as long as
there are no medical contraindications. 
Surgery 
In the hands of an expert parathyroid surgeon, parathyroidec-
tomy is a highly successful procedure with infrequent complica-
tions. Both the classic approach of neck exploration, usually
with efforts to examine all four parathyroid glands and the in-
creasingly popular minimimally invasive parathyroidectomy that
uses local rather than general anesthesia are associated with
cure in over 95 percent of cases (55). 
The minimally invasive procedure requires successful preoper-
ative localization of the abnormal parathyroid gland and capa-
bility to measure PTH rapidly in the operating room (56). Pre-
operative blood is obtained for comparison of the PTH concen-
tration with an intraoperative sample obtained minutes after re-
moval of the “abnormal” parathyroid gland. If the level falls by
more than 50 percent immediately following resection, the
gland that has been removed is considered to be the sole
source of overactive parathyroid tissue and the operation is ter-
minated. If the PTH level does not fall by more than 50 per-
cent, the operation is extended to a more traditional one in a
search for other overactive parathyroid tissue. There is a risk
(albeit small) that the minimally invasive procedure may miss
other overactive gland(s) that are less active in the presence of
a dominant gland (57). With advances in imaging technology
and growing experience with minimally invasive parathyroid
surgery, it is likely that these newer approaches will become
more widely used (58-61). 
Results of surgery
Successful surgery cures primary hyperparathyroidism. Long-
term follow up of these patients indicates a 10 to 12 percent
improvement in bone density at the lumbar spine and femoral
neck over 10 years (51, 62). Most of the gains are seen within
the first three to four years after successful parathyroid surgery.
Postmenopausal women show a similar pattern of increased
cancellous bone density. In patients who have nephrolithiasis,
surgery is of clear benefit in reducing the incidence of recurrent
stones (63). Vague or constitutional symptoms may or may not
improve after surgery, while hypertension and peptic ulcer dis-
ease, if present, are unlikely to remit. Recently, several cohorts
have been observed with respect to changes in fracture inci-
dence following successful parathyroid surgery. Two reports
from Denmark (64, 65) suggest that fracture incidence might
be reduced after parathyroid surgery. It is not clear how com-
parable such cohorts of operated patients are with subjects
who were followed conservatively, without surgery (66). These
discrepancies emphasize the need for controlled prospective
studies. 
Conservative management of asymptomatic 
hyperparathyroidism
If the guidelines offered by the expert panel convened after the
Workshop on Aymptomatic Primary Hyperparathyroidism are
followed (53), about 40-50 percent of patients with primary hy-
perparathyroidism in the United States will fit into the non-sur-
gical, conservative management category. The natural history
of this cohort indicates that over a 10-year period, patients in
general are remarkably stable (66, 67). The group data show
that serum and urine biochemical parameters are stable. Simi-
larly, in the majority of patients, bone mineral density is un-
changed at lumbar spine, hip and distal radius after 10 years.
When these data for the group as a whole are reviewed more
closely, however, it is clear that some patients who are fol-
lowed without surgery will show changes and thus meet criteria
for surgery. In about 25 percent of these patients followed with-
out surgery over 10 years, guidelines for surgery were met
eventually by virtue of an increasing serum or urinary calcium
or declining bone mineral density (66). The fact that an appre-
ciable number of asymptomatic patients will progress to meet
criteria for surgery emphasizes the need for all these patients
to be monitored. 
Monitoring asymptomatic patients who are not to undergo
surgery
The Panel of the 2002 Workshop on Asymptomatic Primary
Hyperparathyroidism recommended a plan for monitoring pa-
tients who are not to undergo parathyroid surgery (Table II).
The serum calcium measurement should be made every six
months, while it is not considered necessary to monitor the uri-
nary calcium excretion on a regular basis. Renal function can
Table I - Indications for surgery in asymptomatic primary hyperpa-
rathyroidism.
Serum calcium (above normal) > 1.0 mg/dL
24-h urinary ca > 400 mg/24 hours
Creatinine clearance > 30% below expected
Bone density T-score <-2.5 at any site
Age < 50
From reference #53.
Table II - Monitoring asymptomatic primary hyperparathyroidism.
Measurement Guidelines
Serum calcium Semiannually
Urinary Ca Not recommended*
Creatinine Clearance Not recommended*
Serum Creatinine Annually
Bone density Annually (3-sites)
Abdominal X-ray ± ultrasound Not recommended*
It is assumed that these tests were obtained as part of the initial evaluation. 
From reference #53.
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be monitored by the yearly serum creatinine concentration and
the Cockcroft-Gault relationship (68). The panel emphasized
the utility of measuring annually bone density at the lumbar
spine, hip and distal 1/3 radius site. 
Medical management
Hydration. It is important that patients maintain adequate hydra-
tion, particularly in summer and warm climates when fluid losses
can be substantial. Thiazide diuretics are to be avoided because
they can worsen hypercalcemia. Careful monitoring may be
needed if patients must undergo prolonged immobilization as with
major trauma. In such instances, the importance of hydration
needs to be emphasized. Under these circumstances, the
asymptomatic patient with primary hyperparathyroidism can
rapidly develop marked hypercalcemia if hydration is not ensured.
Diet. Conventional wisdom suggests that patients should limit
their dietary calcium intake because of the hypercalcemia. Many
patients are given this advice by their own physicians. A counter
argument, however, suggests that low calcium diets could lead
to further increases in PTH levels as they do in normal individu-
als (69, 70). Given the fact that patients with primary hyper-
parathyroidism maintain some sensitivity to ambient calcium
concentrations, even though the sensitivity is impaired, diets re-
stricted in calcium could fuel processes associated with in-
creased production of PTH. The logic of this argument could
lead to diets that are enriched in calcium with the idea that such
a challenge could suppress PTH levels in primary hyperparathy-
roidism, as shown by Insogna et al. (71). Levels of 1,25(OH)D
have to be taken into account in this discussion, since patients
with primary hyperparathyroidism typically have concentrations
of this active metabolite that are at or above the upper limit of
normal. The data of Locker et al. (72) are of interest in this re-
gard. In subjects with elevated levels of 1,25(OH)2D3, high calci-
um diets were associated with worsening hypercalciuria. 
The prudent advice is that dietary calcium intake should be in
the lower end of the range that is generally recommended for
the non-hyperparathyroid population, namely approximately
1000 mg/day. If the 1,25(OH)2D level is increased, calcium in-
take should be more limited. Similarly, calcium-enriched diets
to levels greater than 1500 mg should also be avoided.
Pharmacological approaches. At the time of the 2002 Workshop,
it was concluded that there were no specific medical or pharma-
cological therapies for which there was yet convincing evidence
of efficacy and/or safety (53). Since that time, experience has
accumulated with several of these therapies. These include the
report from the Women’s Health Initiative (73) that emphasizes
increased risks for long-term estrogen alone or with progestin.
Even without this evidence, there was little clear rationale for
long-term estrogen use despite its documented ability at higher
doses (1.25 mg or occasionally more) to lower calcium to normal
without increasing PTH levels (74). Side-effect profile and the
newer data about risk (73) would seem to limit its applicability.
Experience has suggested, however, that selective estrogen re-
ceptor modulators, bisphosphonates and calcimimetics do have
promise as specific pharmacological treatments.
In certain patients, such pharmacological approaches to the
management of hyperparathyroidism are particularly desirable,
such as those who meet guidelines for parathyroid surgery but
refuse surgery or have medical contraindications. For those
who do not meet surgical guidelines, approaches that safely
lower serum calcium or increase bone density are attractive.
These pharmacological approaches to control hypercalcemia
are also useful in patients with parathyroid carcinoma when re-
peated attempts to resect malignant tissue have ultimately
failed. In this section, we describe cumulative experience with
pharmacological approaches. 
Selective Estrogen Receptor Modulators (SERMS). The SERM,
raloxifene, is a potential alternative to estrogen. Rubin et al. (75)
studied 18 postmenopausal women with hyperparathyroidism.
They were randomly allocated to an eight-week course of ralox-
ifene (60 mg/day) or placebo. There was a four-week follow up
period off therapy. In the raloxifene group, the average serum cal-
cium fell significantly from 10.8 ± 0.2 mg/dl to 10.4 ± 0.2 mg/dl (P
< 0.05). The placebo group did not show any change in the
serum calcium over this period of time. Along with the reduction
in serum calcium, markers of bone formation and bone resorption
fell. The bone formation marker, osteocalcin, fell significantly from
11.1 ± 1.6 to 9.9 ± 1.6 nmol/l (P < 0.05). The bone resorption
marker, serum N-telopeptide also fell significantly from 21.2 ± 3.4
to 17.3 ± 2.8 nmol bone collagen equivalents/l (P < 0.05). Again
the placebo group did not show any change in either of these two
bone turnover markers. After the four-week period off therapy, the
group that had received raloxifene returned to baseline in terms
of the serum calcium and bone turnover markers. Raloxifene ad-
ministration was not associated with any changes in serum PTH,
1,25(OH)2D or urinary calcium excretion (75). In a open pilot
study of only three patients, but carried out for a year, Zanchetta
and Bogado (76) showed a similar reduction in serum calcium
with raloxifene and increases in bone mineral density of the lum-
bar spine and femoral neck. These promising data, which need to
be followed up with more definitive observations, hold promise for
a potential role that raloxifene might have in selected post-
menopausal women with primary hyperparathyroidism. 
Bisphosphonates. The conceptual basis for expecting that bis-
phosphonates have potential as a medical approach to primary
hyperparathyroidism is evident. Primary hyperparathyroidism,
even in patients who are asymptomatic, is frequently associated
with increases in bone turnover (77). By reducing bone resorp-
tion, without affecting PTH secretion directly, bisphosphonates
could reduce serum and urinary calcium levels. An additional po-
tential benefit of bisphosphonates in primary hyperparathy-
roidism would be to increase bone mineral density. Early studies
with the first-generation bisphosphonates, etidronate and clo-
dronate, however, were disappointing (78). The fall in serum cal-
cium was not sustained. Experience with alendronate has been
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Figure 2 - Alendronate in primary hyperparathyroidism. Bone mineral
density (BMD) of the lumbar spine in patients treated with alendronate.
The group that was treated initially showed a significant increase after 1
year which was maintained in year 2. In the group that received place-
bo, there were significant gains only when they were crossed over to al-
endronate in year 2. Significance from baseline is noted by the aster-
isks. (Adapted from reference #82).
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more encouraging. Two well-controlled doubled-blinded random-
ized clinical trials, following several open label studies (79, 80),
have been conducted (81-83). The study of Khan et al. (82) was
a randomized, placebo-controlled, study of 44 patients who were
administered either alendronate 10 mg daily or placebo (Fig. 2).
After 12 months, patients taking placebo were “crossed over” to
take alendronate. Those who were taking alendronate in year
one continued to take drug in year two. The primary outcome
measure was the change in bone mineral density at all three
sites. In comparison to baseline, treatment with alendronate was
associated with a significant 6.85 ± .94 percent (P < 0.001) in-
crease in bone mineral density of the lumbar spine after two
years. Total hip bone mineral density also increased significantly
in comparison to baseline by 4.01 ± .77 percent (P < 0.001).
There was no significant change at the distal one-third radius
site. When the placebo group, that did not show any change in
year one, was crossed over to alendronate at 12 months, there
was a significant 4.1 ± 1.12 percent increase in lumbar spine
bone density (P = 0.003). The hip bone mineral density also in-
creased at year two in the crossover group. As expected, alen-
dronate was associated with substantial reductions in bone
turnover markers. Urinary N-telopeptide fell by 66 percent and
bone-specific alkaline phoshphase activity fell by 49 percent at 3
and 6 months respectively (P < 0.001). There were no changes
in serum or urine calcium or serum PTH in either group. The ex-
perience of Chow et al. (81) in their one-year randomized, place-
bo-controlled trial of alendronate in primary hyperparathyroidism
is remarkably similar to the study of Khan et al. (82). The only
major difference was a significant alendronate-associated reduc-
tion in the serum calcium, by 0.34 mg/dl (P < 0.02). The only ex-
perience with risedronate was an acute, seven-day study of 19
patients with primary hyperparathyroidism in which the serum
and urinary calcium fell significantly (83). These encouraging re-
sults suggest there may be a role for bisphosphonate therapy,
specially in patients who are poor operative risks.
Calcimimetics. A more targeted approach to the medical thera-
py of primary hyperparathyroidism is to interfere specifically
with the production of PTH. A new class of agents that alters
the function of the extracellular calcium-sensing receptor offers
an exciting new approach to primary hyperparathyroidism. By
binding to an allosteric site, these agents increase the affinity
of extracellular calcium for the calcium receptor, leading to re-
duction in PTH secretion. Such agents, therefore, could con-
ceivably be utilized to reduce PTH and serum calcium levels in
hyperparathyroid states. An early clinical experience with post-
menopausal women who had mild primary hyperparathy-
roidism showed that, in principle, a calcimimetic can significant-
ly reduce PTH and serum calcium levels in this disease (84).
More recent experience has been gained with a newer cal-
cimimetic, cinacalcet. This agent has been studied in the hy-
perparathyroidism associated with renal failure, in primary hy-
perparathyroidism and in parathyroid cancer (85). So far,
cinacalcet has been approved by the FDA only for the man-
agement of patients in renal failure on dialysis with secondary
hyperparathyroidism and in patients with parathyroid carcino-
ma. Even though the drug has not been approved yet for pri-
mary hyperparathyroidism, the early data are promising.
Shoback et al. (86) studied 22 patients with primary hyper-
parathyroidism. In this dose-ranging study, patients were given
placebo or drug in amounts of 30, 40, or 50 mg twice daily for
15 days. In all dose groups, except placebo, cinacalcet was as-
sociated with a normalization of the serum calcium after the
second dose and remained within normal limits for the entire
two-week period. Maximal reductions in PTH, over 50 percent,
occurred two to four hours after dosing in all cinacalcet-treated
groups. This reduction occurred when tested at both day one
and day two of the study. There were no significant changes in
urinary calcium excretion. Both serum calcium and PTH re-
turned toward baseline by seven days after cinacalcet was
stopped. Peacock et al. (87) have recently reported their expe-
rience in a longer study of cinacalcet. This multicenter, ran-
domized, double-blind, placebo-controlled trial was designed to
evaluated the longer term actions of cinacalcet in 78 patients
with primary hyperparathyroidism. Cinacalcet was titrated from
30-50 mg twice daily during a 12-week period followed by a 12-
week maintenance and 28-week follow-up period. Most pa-
tients treated with cinacalcet achieved the primary endpoint,
namely normocalcemia (Fig. 3). Normal calcium concentrations
were maintained for the entire duration of the study. Modest,
but significant, reductions in the plasma PTH concentration
were observed in the cinacalcet group. Similar to the study of
Shoback, PTH levels fell quickly within hours after the adminis-
tration of drug. This experience has been extended to three
years over which time the majority patients with primary hyper-
parathyroidism who were treated with cinacalcet demonstrated
excellent maintenance of a normal serum serum calcium con-
centration (88). 
The calcimimetics have also been studied in parathyroid carci-
noma. The first experience was a patient with end-stage
parathyroid carcinoma and intractable hypercalcemia treated
with R-568 (the first-generation calcimimetic) whose serum cal-
cium fell from a pretreatment value over 17 mg/dl to 11-12
mg/dl (89). Over the course of the next two years, the serum
calcium was controlled to within 1-1.5 mg/dl above the upper
limits of normal. The PTH levels fell to approximately 30 per-
cent below pretreatment values. With cinacalcet, promising re-
sults have been gained in 21 patients with parathyroid cancer
(90, 91). These individuals were all highly symptomatic of dif-
fuse, disseminated parathyroid cancer with marked hypercal-
cemia (average >14.5 mg/dl) and extremely high PTH levels.
With titration up to a maximal dosage of 360 mg in four divided
doses, serum calcium levels fell to an average of 12.4 mg/dl.
Control of the serum calcium could be demonstrated in some
patients for up to three years. The PTH level did not uniformly
fall; in some patients there was an increase in PTH, despite the
reduction in serum calcium. Nevertheless, after a given dose of
cinacalcet in these patients, a rapid, but transient fall in PTH
could be demonstrated. 
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Figure 3 - Cinacalcet in primary hyperparathyroidism. Serum calcium of
a group of subjects is shown after treatment with cinacalcet (30 mg
twice daily) or placebo. The serum calcium quickly normalized and was
maintained for the 52 week treatment period whereas subjects treated
with placebo maintained mild hypercalcemia. The normal range is
shaded (Adapted from reference #87). 
Week
m
g/
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Summary
As experience with asymptomatic primary hyperparathyroidism
has grown over the past three decades, new approaches in di-
agnosis, evaluation, and treatment have emerged. Growth in
knowledge about the natural history of this disorder suggests
that certain patients can be safely followed without surgery. On
the other hand, in all patients with the disease, if medical sta-
tus permits, surgery is always an acceptable option, especially
with improvements in minimally invasive parathyroidectomy
and the knowledge that bone mineral density improves signifi-
cantly as a result of surgical correction of the disease. Revised
guidelines are offered that can serve to direct physicians and
patients in their choice of treatment options while balancing
risks and benefits of the decision made. Increasing experience
with specific pharmacological treatments shows promise as yet
another alternative to surgery or simple medical monitoring. 
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